<DOC>
	<DOCNO>NCT01902329</DOCNO>
	<brief_summary>This study examine safety profile vadastuximab talirine ( SGN-CD33A ) administer single agent combination hypomethylating agent ( HMA ) . The main purpose study find maximum tolerate dose ( MTD , high dose cause unacceptable side effect ) SGN-CD33A patient acute myeloid leukemia ( AML ) . The MTD determine observe dose-limiting toxicity ( side effect prevent increase dose ) SGN-CD33A . In addition , pharmacokinetic profile anti-leukemia activity SGN-CD33A assess .</brief_summary>
	<brief_title>A Safety Study SGN-CD33A AML Patients</brief_title>
	<detailed_description>This study explore SGN-CD33A monotherapy combination hypomethylating agent ( HMA ; i.e. , azacitidine decitabine ) . Initial study treatment SGN-CD33A include maximum 2 cycle treatment monotherapy 4 cycle combination cohort . Patients achieve document CR CRi ( Monotherapy ) clinical benefit ( Combination ) first part study eligible continue treatment . Additional monotherapy cohort may include patient relapsed acute promyelocytic leukemia , relapse patient nucleophosmin-1 gene mutation ( absence fms-like tyrosine kinase 3 mutation ) ( NPM1-mutated , FLT-3 wild type ) , alternate dosing schedule ( fractionate dosing Days 1 4 ) , treatment naive patient AML decline intensive therapy , patient relapse post-allogeneic stem cell transplant . Patients combination cohort treat azacitidine decitabine per institutional practice prior SGN-CD33A dosing . Expansion cohort may add evaluation safety , pharmacokinetics , pharmacodynamics , antitumor activity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>Acute myeloid leukemia , positive CD33 Eastern Cooperative Oncology Group status 0 1 Adequate baseline renal hepatic function Central venous access Either achieve complete remission ( great 12 week duration ) initial induction/consolidation experience relapse disease decline treatment highdose induction/consolidation Bone marrow blast great equal 5 % relapsed patient , great equal 20 % untreated patient Inadequate lung function Prior allogeneic stem cell transplant , except specific cohort Highdose chemotherapy within 4 week study drug Antileukemia treatment within 14 day study drug ( hydroxyurea 6mercaptopurine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>CD33 Antigen</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Promyelocytic Leukemia</keyword>
	<keyword>APL</keyword>
</DOC>